Shilpa Medicare, founded in 1989, is a producer and marketer of pharmaceutical products. The company has a special focus on oncology. It also conducts research and development of drugs and drug formulations and is taking steps towards developing novel drug delivery systems and biotech products. Shilpa Medicare has branch offices and production units across India and its corporate office in Raichur, Karnataka.
On 13 February 2023, the market capitalisation of the company was Rs 2,083.68 crore. It reported consolidated sales of Rs 68.7 crore at the end of September 2022. The company is listed on the Bombay Stock Exchange with the code 530549 and the National Stock Exchange with the code SHILPAMED.
On 31 December 2022, the company’s shareholding pattern indicated a promoter stake of 50.01%. The foreign institutional investor stake in the company was 15.32%. Domestic mutual funds and other domestic institutional investors held a stake of 0.61%. Retail investors and others held a stake of 34.06% in the company. The shareholding pattern has remained largely consistent over the past year.
The company’s board of directors comprises Omprakash Inani, Vishnukant Chaturbhuj Bhutada, Sharath Reddy Kalakota, Anita Bandyopadhyay, Arvind Vasudeva, Hetal Madhukant Gandhi, Kamal K Sharma, Sirisha Chintapalli, and others. The auditors are Bohara Bhandari Bung & Associates LLP and Brahmayya & Co. On 30 September 2022, the company had a total of 8.68 crore shares outstanding.
On 13 February 2023, Shilpa Medicare’s share price on BSE was Rs 241.10 and Rs 241.60 on NSE. The share price touched a 52-week high of Rs 509.00 and a 52-week low of Rs 231.80. Its three-month return to investors was -19.08%, while its one-year return was -50.19%.
On November 2022, Nippon India Nifty Smallcap 250 Index Fund Direct-Growth had invested Rs 0.48 crore in the company while Motilal Oswal Nifty Smallcap 250 Index Fund Direct-Growth and SBI Nifty Smallcap 250 Index Fund Direct-Growth had invested Rs 0.39 crore and Rs 0.18 crore, respectively.
On November 2022, the company had a trailing-twelve-month (TTM) revenue of Rs 1,145.52 crore. The company also had a net profit of Rs 60.58 crore during the same period.
Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code: 07730), BSE Ltd (Member Code: 103) and Member of Multi Commodity Exchange of India Ltd.(Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Ms. Mamta Shetty, Contact number: 022-40701022, E-mail address: email@example.com. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Such representations are not indicative of future results. The securities quoted are exemplary and are not recommendatory. Investors should consult their financial advisers if in doubt about whether the product is suitable for them. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.